UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 ___________________________________ Pulse Bioscienc ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________________ Form 10-Q ___________________________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2019 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 ___________________________________ Pulse Bioscien ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q1 2019 Earnings Conference Call April 30, 2019 4:30 PM ET Company Participants Brian Dow – Senior Vice President and Chief Financial Officer Darrin Uecker – President and Chief Executive Officer Ed Ebbers – Vice President and General Manager-Dermatology Conference Call Participants Swayampakula Ramakanth – H.C. Wainwright Operator Good day, ladies and gentlemen and welcome to the Pulse Biosciences First Quarter 2019 Investor and Analyst Call. At this time, all particip ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------------------------------------------------------------------------------------------|-------|-------------------|-------|-------|-------| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | Pulse Biosciences | | | | | electromedicine company bringing to market their CellFX™ System, utilizing groundbreaking Nano-Pulse Stimulation TM (NPS) technology | | | | | | | | | | | | | 1 Forward-look ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________ Form 10-K ____________________________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-34899 _____________________________________ ...

Pulse Biosciences, Inc. (NASDAQ:PLSE) Q4 2018 Earnings Conference Call February 7, 2018 4:30 PM ET Company Participants Darrin Uecker - Chief Executive Officer Brian Dow - Senior Vice President and Chief Financial Officer Ed Ebbers - Executive Vice President and General Manager of Dermatology Conference Call Participants Operator Good day, ladies and gentlemen and welcome to the Pulse Biosciences Investor Update Conference Call. At this time, all participants are in a listen-only mode. Later we will conduct ...